SOCS3 and metabolic dysfunction-associated steatotic liver disease: For instance, in “Non-alcoholic fatty liver disease” pathway, IL6 activates its receptor IL6R and regulates the activity of lipogenic enzymes through SOCS3 and SREBP-1c to influence de novo fatty acid synthesis.